跳到正文
MarketHOT
English
摘要
SEC · EDGAR 财务披露·· 11 天前AI 评分37

Silexion Therapeutics 宣布实施 1 比 24 反向拆股

Silexion Therapeutics Corp (0002022416) (Filer)

AI 导读

Silexion Therapeutics 于 11 月 9 日宣布,已获股东批准的 1 比 24 反向拆股将在 11 月 10 日收市后生效,普通股将于 11 月 11 日开市起按拆股调整后基础交易。股票代码仍为 SLXN,面值将从每股 0.135 美元升至 3.24 美元;拆股自动进行,零碎股向上取整。

正文

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 9, 2026

Silexion Therapeutics Corp
(Exact name of registrant as specified in its charter)

Cayman Islands   001-42253   N/A
(State or other jurisdiction   (Commission File Number)   (I.R.S. Employer
of incorporation)       Identification No.)

12 Abba Hillel Road

Ramat-Gan, Israel

  5250606
(Address of principal executive offices)   (Zip Code)

+972-3-7564999

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Ordinary Shares, par value $0.135 per share   SLXN   The Nasdaq Stock Market LLC
Warrants exercisable for Ordinary Shares at an exercise price of $15,525.00 per share   SLXNW   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

Further to its previous reports, as well as the approval of its shareholders received on October 26, 2026, on November 9, 2026, Silexion Therapeutics Corp, a Cayman Islands exempted company (“Silexion” or the “Company”) issued a press release announcing a prospective 1-for-24 reverse share split of all of its issued and outstanding, and authorized but unissued, ordinary shares. The reverse share split will become effective after the close of the market on November 10, 2026, and the Company’s ordinary shares will begin trading on a reverse split-adjusted basis on the Nasdaq Capital Market at the open of the market on November 11, 2026. The ticker symbol for the ordinary shares will remain “SLXN.”

The reverse share split will be effected automatically, without any action required on the part of the Company’s shareholders. The reverse share split will result in a corresponding increase in the par value of the Company’s ordinary shares, from $0.135 per share to $3.24 per share. No fractional shares will be issued as a result of the reverse share split, as any fractional share totals as to which shareholders who are DTC participants become entitled will be rounded up to the nearest whole number of shares. A copy of the press release announcing the reverse share split is attached as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits 

(d) Exhibits

99.1   Press Release dated November 9, 2026, titled “Silexion Therapeutics Announces 1-for-24 Reverse Share Split”

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  SILEXION THERAPEUTICS CORP
   
Date: November 9, 2026 /s/ Ilan Hadar
  Name: Ilan Hadar
  Title: Chief Executive Officer

来源:SEC EDGAR · 本站存档